Log in or Sign up for Free to view tailored content for your specialty!
Cell Therapy News
FDA approves Breyanzi CAR-T for chronic lymphocytic leukemia, small lymphocytic lymphoma
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Multi-engineered CAR-T confers significant, rapid reduction of aggressive brain tumor
A novel chimeric antigen receptor T-cell therapy produced significant tumor reductions in patients with glioblastoma, results from a phase 1 trial published in The New England Journal of Medicine showed.
Log in or Sign up for Free to view tailored content for your specialty!
Risk factors identified for secondary leukemia in patients who received CAR T cells
Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.
CAR-T shows ‘superior outcomes’ in adults with post-transplant relapsed leukemia
Patients with post-transplant relapsed B-cell acute lymphoblastic leukemia who received chimeric antigen receptor T-cell therapy had superior outcomes compared with alternative approaches, study results showed.
BLOG: Caring for patients receiving adoptive cellular therapy
Adoptive cellular therapies such as chimeric antigen receptor T-cell therapy have transformed the landscape of care for patients with relapsed or refractory hematologic malignancies.
Health care professionals enthusiastic about approval of first cell therapy for melanoma
An analysis of global online conversations among health care professionals on social media in February showed an overarching sense of enthusiasm about FDA approval of the first cellular therapy to treat unresectable or metastatic melanoma.
Liquid biopsy offers ‘meaningful approach’ to understanding CAR-T
Liquid biopsy could provide enhanced information about chimeric antigen receptor T-cell therapy compared with normally used DNA, RNA and protein assays, according to findings published in Journal for ImmunoTherapy of Cancer.
‘Off-the-shelf’ cell therapy shows ‘very encouraging’ results for B-cell malignancies
Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.
‘Gratifying’ results show ‘incredible step forward’ for off-the-shelf T-cell therapies
The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
AACR to honor Steven A. Rosenberg, MD, PhD, for lifetime achievement in cancer research
Steven A. Rosenberg, MD, PhD, FAACR, will be awarded the 2024 American Association for Cancer Research Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting in San Diego.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read